New stem cell approach targets functional cure for diabetes

Type 1 diabetes remains one of the most complex chronic conditions in modern medicine. The key cause of this condition is the loss of pancreatic beta cells, which normally make insulin for the body. Because of this, people with the condition must regularly check their blood sugar and rely on insulin treatment throughout their lives. Against this backdrop, stem cell therapy is regarded as one of the most promising areas of research, as it focuses not on compensating for the disease, but on restoring the body’s lost function.

What is this new method?

In July 2026, the findings from studies on creating an advanced form of cell-based treatment for people living with type 1 diabetes were shared. The research examines a new method in which stem cells are turned into cells that release insulin. After that, the cells are modified to help them survive without being destroyed by the body’s immune defenses. One of the greatest barriers to successful diabetes cell therapy has been the immune system, which often rejects the transplanted cells. Even when transplantation was successful, the body recognised the new cells as foreign and gradually destroyed them. To maintain the results, patients required long-term use of immunosuppressants, which significantly limited the potential for widespread use of such technologies.

How scientists are trying to tackle the problem of immune rejection

A new approach offers a solution to this very problem. Researchers are using immune engineering techniques to make the cells less recognizable to the immune system. It is hoped that, following transplantation, such cells will be able to maintain their ability to produce insulin for a long time without the need for constant suppression of the immune response. If the technology’s effectiveness is confirmed in further studies, this will significantly expand the range of patients who may have access to this type of therapy.

What areas of cell therapy are currently being developed?

The development of stem cell technologies for the treatment of diabetes is proceeding along several fronts simultaneously. Some research groups are working on cultivating new beta cells from the patient’s own cells. Others are focusing on universal donor cell lines. A separate area of research involves the use of genome editing technologies to protect transplanted cells from autoimmune attacks. The possibility of industrial-scale production of insulin-producing cells is of particular interest. Successful results from extensive clinical testing would make it possible to introduce this treatment to a much larger patient population. This form of treatment may be of interest to a number of patients.

What stage is the research at?

Despite the high level of interest in the development, experts emphasise that the technology is still at the clinical trial stage. It is necessary to confirm the long-term safety of the method, assess the stability of insulin production and determine the duration of the therapeutic effect. The question of treatment costs also remains unresolved. As experience with the introduction of innovative biomedical technologies shows, such methods usually remain expensive in the first few years after market launch and are accessible only to a limited number of patients. Over the past few years, the field of cell therapy for diabetes has made significant progress. Until recently, the focus was exclusively on laboratory experiments, whereas today there are already patients who, following cell transplantation, have been able to stop taking insulin for an extended period. This is changing attitudes towards the disease and shaping a new treatment strategy focused on restoring pancreatic function, rather than merely controlling blood sugar levels. 

Eternity Life Tourism specialises in this field and supports patients at every stage of organising treatment abroad. The company collaborates with specialist medical centres and clinics specialising in regenerative medicine in various countries, including institutions specialising in the application of cell technologies and stem cell therapy.

FAQ